The European Hematology Association is highly committed to organize fully compliant and independent educational and scientific meetings.
The Exhibitor or Sponsor showcasing pharmaceutical (or pharma-dependent) products is advised to consult the advice of the Codes of Practice for the Promotion of Medicines presented by the European Federation of Pharmaceutical Industries and Associations (EFPIA) and the Pharmaceutical Research and Manufacturers of America (PhRMA) bodies before applying. In all cases, the Exhibitor or Sponsor is responsible for ensuring that their promotion during the Congress is legally and ethically acceptable in Sweden. EHA is not liable in any way for sponsors not complying to legal, ethical and industry standards.
To access the status of EHA23 on EFPIA, please follow this link.
The MedTech Europe Code of Ethical Business Practice regulates all aspects of the industry’s relationship with Healthcare Professionals (HCPs) and Healthcare Organisations (HCOs), such as company-organised events, arrangements with consultants, research and financial support to medical education, amongst others.
The 2018 Annual congress edition is confirmed to be compliant. You can verify the status of EHA23 via this link.
MCI Group, EHA’s appointed Professional Congress Organizer, has completed the process for the MedTech Ethical Charter. This certificate ensures that MCI commits to the appropriate application of the MedTech Europe Code provisions to the educational events for which MCI seeks industry’s financial support, such as the 23rd Congress of the European Hematology Association to take place June 14 – 17, 2018 in Stockholm, Sweden.
Each company is responsible for conducting its business in full compliance with all national and international laws and regulations that pertain to its particular industry, and that prior to their application a compliance officer has approved the specific sponsorship item(s).